Solventum SOLV
United StatesHealthcare · Medical Instruments & SuppliesUSD
94.31 USD (+9.8%)
13 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Solventum Corporation is a healthcare company offering medical products and solutions, including surgical supplies, wound care, and health information technology, following its spin-off from 3M.
Key points
from its scores- ✓Good share-price trend7.7
- ✓Favourable backdrop7.1
- ✕Little or no dividend1.5
- ✕Fragile balance sheet3.5
- !Moderate growth5.0
AI analysis
bottom line, main risk, context and newsThe cheap valuation and strong ROE offset debt risk, but it is only attractive if it reduces leverage and demonstrates sustained growth.
Solventum shows fragile financial health (Net Debt/EBITDA of 4.29) but solid quality (ROE of 33.96%) and attractive valuation (P/E of 10.51), with moderate growth and no dividend; positive momentum (24.01%) suggests recovery, though leverage and high rates limit its appeal.
High leverage (Net Debt/EBITDA of 4.29) and exposure to legacy 3M litigation are the biggest risk, especially with rising interest rates making its debt more expensive.
Context and risks
Solventum, spun off from 3M, operates in a regulated U.S. healthcare sector with exposure to legacy litigation and pricing pressure on medical devices. The country's moderate governance risk and its high debt structure (Net Debt/EBITDA of 4.29) amplify its sensitivity to a rising rate environment, though its medical supplies business does not depend on commodities or geopolitical routes.
Is Solventum stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 21% below the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 10.5 | 26.7 | −61% |
| EV / EBITDA | 17.1 | 14.5 | +18% |
| Price / book | 3.0 | 4.1 | −26% |
| Price / sales | 1.8 | 3.4 | −49% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 6.4 out of 10 (median for Healthcare: 4.7).
Average analyst target: 94.31 USD, +9.8% versus the price.
A discount may reflect more risk or slower growth than its sector: Financial health 3.5 (sector 6.5), Growth 5.0 (sector 6.6).
Classic formulas with standard assumptions (0.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 10.5
- Forward P/E
- 11.9
- EV / EBITDA
- 17.1
- Price / book
- 3.0
- Price / sales
- 1.8
- PEG
- 1.22
- Market cap
- 14.6B USD
- Enterprise value
- 19.5B USD
Profitability
- ROE
- 34.0%
- ROA
- 2.7%
- ROIC (approx.)
- 8.1%
- Gross margin
- 54.8%
- Operating margin
- 9.8%
- Net margin
- 17.3%
- Free cash flow
- 489.0M USD
- FCF yield
- 3.3%
- Cash conversion
- 43%
Solvency
- Total debt
- 5.3B USD
- Net debt
- 4.9B USD
- Cash
- 403.0M USD
- EBITDA
- 1.1B USD
- Net debt / EBITDA
- 4.29
- Debt / equity
- 110.31
- Current ratio
- 1.02
- Quick ratio
- 0.50
Growth
- Revenue growth
- +2.2%
- Earnings growth
- +3.9%
- EPS (TTM)
- 8.17 USD
- EPS (forward)
- 7.23 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.70
- Analyst consensus
- Buy (13)
- Target price
- 94.31 USD
- 52-week range
- 62.38 – 94.16
Recent news
All SOLV news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Solventum
Is Solventum stock cheap or expensive?
On P/E and EV / EBITDA, it trades 21% below the Healthcare median on average. Valuation score: 6.4 out of 10 (median for Healthcare: 4.7). Average analyst target: 94.31 USD, +9.8% versus the price. This is not investment advice.
What score does Solventum get on MeridIAn Screener?
It scores 5.6 out of 10, rank 1,371 of 2,130 (better than 35% of the companies analysed). Its strongest category is Momentum (7.7) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is Solventum's P/E ratio?
Its P/E is 10.5: the share price equals 10.5 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 11.9.
How much is Solventum worth on the stock market?
Its market capitalisation is 14.6B USD and its enterprise value, debt included, is 19.5B USD.
How much debt does Solventum have?
Its net debt (debt minus cash) is 4.9B USD. That is 4.29 times its EBITDA; the Healthcare median is 1.53.
Does Solventum pay a dividend?
It pays no dividend, or almost none.
How has Solventum stock performed over the last year?
It has risen 21.8% over the last year, excluding dividends. Over the last 52 weeks it has traded between 62.38 and 94.16 USD. Past performance does not guarantee future results.
What do analysts think of Solventum?
13 analysts cover it; their average recommendation is “Buy” and their average target is 94.31 USD (+9.8% versus the price). It is an estimate, not market data.